Role of Faecal Calprotectin in Patients With Abdominal Pain

Role of Faecal Calprotectin in Patients Presenting to the Emergency Department With Abdominal Pain

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05795985

Enrollment

146

Registered

2023-04-03

Start date

2021-07-01

Completion date

2023-03-01

Last updated

2023-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammation

Brief summary

The evaluation of patients with abdominal pain is a challenge for the emergency physician and the selection of patients for second-level radiological examinations or endoscopic procedures is not always easy to perform. Faecal calprotectin could be a useful diagnostic marker to distinguish between organic or functional form and its determination could be helpful to select patients for further examinations, in the context of emergency setting.

Interventions

DIAGNOSTIC_TESTcalprotectin levels

dosage of calprotectin levels in patients with abdominal pain

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* patients with abdominal pain and/or diarrhea and/or rectal bleeding

Exclusion criteria

* patients with age \< 18 years * pregnant women; * patients with oncological, cardiological, nephrological terminal diseases; * patients on antibiotic therapy or who have taken it during the last month; * patients with a history of colic resection or gastrointestinal surgery; * patients with a previous diagnosis of inflammatory bowel disease (Crohn's disease, ulcerative colitis)

Design outcomes

Primary

Measure	Time frame	Description
inflammation	3 days	assess the degree of intestinal inflammation by fecal calprotectin assay in patients with abdominal pain

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026